Those with treatment-resistant depression showed significant improvement in symptoms and became more receptive to positive experiences following a one-week ketamine treatment regimen.
Combining deep-brain stimulation with intracranial EEG, researchers achieved an individualized understanding of specific brain networks that contributed to an individual's depression symptoms and identified stimulation patterns best suited to each patient for symptom relief.
Low amplitude electroconvulsive therapy (ECT) lowers suicidal ideation in patients with major depressive disorder and bipolar depression, a new small randomized pilot study reveals. Within just three sessions, patients reported relief from suicidal thoughts.
Deep brain stimulation provides a significant reduction in the symptoms of depression for a number of patients with a treatment-resistant form of the disorder.
Researchers use CRISPR gene editing technology to target GABA receptors in order to help treat mood disorders.
A new study reports patients with major depressive disorder and treatment resistant depression have decreased levels of acetyl-L-carnitine in their blood. The findings could lead to new blood tests to diagnose the nature and severity of depression.
Ayahuasca, a psychedelic drink made from Amazonian plants, may help relieve symptoms in those with treatment resistant depression, researchers report.
Months after receiving psilocybin treatments for depression, patients report feeling more connected with nature and experience a shift away from authoritarian political views, researchers report.
Two new studies consider the potential of using psychedelics to help treat depression. Imperial College London researchers report psilocybin, the active compound in magic mushrooms, can help to relieve symptoms of depression without the dulling of emotions associated with SSRIs. The researchers note the psychedelic experience could help to maintain long term mental health for those with treatment resistant depression.
A new study adds to growing evidence supporting the benefits of psychedelics to treat mental illnesses. Researchers report psilocybin, the psychoactive compound in magic mushrooms, is effective in reducing symptoms for people with treatment resistant depression. The study reveals the compound resets the activity of a brain network associated with depression, helping to improve symptoms in patients for up to 5 weeks following treatment.
Researchers report TMS therapy appears to be effective in treating some whose depression can not be improved by conventional medications.
In a new study, researchers report on the potential for using psilocybin, a hallucinogenic compound derived from magic mushrooms, for treating patients with treatment resistant depression.
